Oncologics Will Need Dual Genetic Tests For Optimally Targeted Treatments
The key to successful use of targeted oncologic therapies will be routine genetic testing for both the patient and the tumor, Fox Chase Cancer Center Senior VP Robert Ozols suggested at an American Society of Clinical Oncology briefing Dec. 2
You may also be interested in...
Genentech and OSI Pharmaceuticals will be meeting with FDA early in 2005 to discuss filing plans for Tarceva (erlotinib) in pancreatic cancer
Roche expects to face an upcoming challenge in defining the appropriate pricing model for the next generation of combination cancer therapies
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011